title: Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.
abstract: Many individuals with total blindness can develop a circadian rhythm disorder-called non-24 sleep wake syndrome-because they cannot detect light to resynchronize their sleep-wake cycles. A new melatonin 1 and melatonin 2 agonist tasimelteon improves sleep in these patients, resetting their circadian sleep-wake clocks.
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Stahl
mesh_terms: D001572:Benzofurans / Q000627:therapeutic use*; D001766:Blindness / Q000150:complications*; D003521:Cyclopropanes / Q000627:therapeutic use*; D006801:Humans; D044094:Receptors, Melatonin / Q000819:agonists*; D020178:Sleep Disorders, Circadian Rhythm / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D001572:Benzofurans; D003521:Cyclopropanes; D044094:Receptors, Melatonin; C478745:tasimelteon